Theorem Clinical Research

R&D Trends

Report: Total VC investment in second quarter highest since 2000

Friday, August 29, 2014 10:30 AM

Venture capitalists invested $13 billion in 1,114 deals in the second quarter of 2014, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

More... »


Report: Cancer survival in England improving using cancer staging data

Wednesday, August 27, 2014 01:17 PM

Cancer survival in England for breast, lung, prostate, colorectal and ovarian cancer continues to improve, according to new data published in a report from Public Health England’s National Cancer Intelligence Network (NCIN).

More... »


Expression Analysis, Illumina launch 2014 grant program

Monday, August 25, 2014 02:13 PM

Expression Analysis (EA), a Quintiles company based in Research Triangle Park, N.C., is co-sponsoring a grant program that provides scientists with leading-edge products and services to advance genomics research.

More... »

OncoSynergy launches ebola treatment crowdfunding campaign

Monday, August 25, 2014 02:09 PM

OncoSynergy, a University of California San Francisco spinoff focused on addressing unmet needs in oncology, particularly orphan cancers, has launched a crowdfunding campaign to fund a study testing its experimental cancer drug, OS2966, for ebola infection.

More... »

Initiative for emergency Ebola research formed by Wellcome Trust, U.K. government

Friday, August 22, 2014 11:59 AM

A $10.8 million emergency funding package for research to contain the Ebola epidemic in West Africa and future outbreaks of infectious disease has been initiated by the U.K-based Wellcome Trust and the U.K. Department for International Development, administered by Enhancing Learning and Research for Humanitarian Assistance (ELRHA).

More... »

Medical Research Council finds flaws with U.K. molecular pathology landscape

Friday, August 22, 2014 11:56 AM

The Medical Research Council (MRC) has published a review of the U.K.’s capabilities in molecular pathology—the discipline that uses analysis of the molecules within tissue and body fluids to aid in a more accurate diagnosis and monitoring of disease. The review identifies three areas which, if not addressed, could inhibit the discovery, development and adoption of innovative diagnostic tests that will ultimately offer clinical, economic and research benefits.

More... »

ViaCyte, Janssen R&D ink agreement

Friday, August 22, 2014 11:54 AM

ViaCyte, a San Diego-based, privately held regenerative medicine company, has entered into a $20 million rights agreement with Janssen R&D, a unit of Johnson & Johnson. The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01 combination product that ViaCyte is developing for type 1 diabetes. This right will continue through the initial evaluation of clinical efficacy of VC-01. 

More... »

Report: Dengue vaccine market to experience rapid growth from 2015 to 2020

Friday, August 22, 2014 11:53 AM

Among the five pharmaceutical markets of Brazil, India, Mexico, Singapore and Thailand, Brazil and Mexico are projected to be the leading contributors to the dengue vaccine marketplace, as it expands rapidly from an estimated $70 million in 2015 to $400 million by 2020, at a Compound Annual Growth Rate (CAGR) of 42%, according to U.K. research and consulting firm GlobalData.

More... »

Emergent BioSolutions, MorphoSys ink agreement for ES414

Friday, August 22, 2014 11:52 AM

Emergent BioSolutions, a Rockville, Md.-based global specialty biopharmaceutical company, and MorphoSys, a Germany-based provider of therapeutic antibodies, have inked an agreement for the joint development and commercialization of Emergent’s preclinical bi-specific antibody, ES414, targeting prostate cancer. Emergent will receive an upfront payment of $20 million and milestone payments of up to $163 million.

More... »

Novartis provides drug candidate compounds to TB Alliance

Thursday, August 21, 2014 01:48 PM

Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance), which has locations in the U.S., Brussels and South Africa, for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs